房颤不良事件的性别差异与当代风险
基于英国初级保健电子健康记录(2005-2020),纳入78 852例40-75岁、无既往卒中且未处方口服抗凝药的房颤患者,女性占36.3%。
要点
- 女性房颤患者主要复合终点风险低于男性,主要由全因死亡率较低驱动。
- 缺血性卒中或动脉血栓栓塞风险无性别差异(校正HR 1.00)。
- 忽略性别的CHA2DS2-VA评分对主要终点预测优于CHA2DS2-VASc。
核心结论
- 从临床风险评分中移除性别可能简化房颤患者口服抗凝药决策流程。
研究设计与样本
- 人群队列研究,使用英国初级保健电子健康记录(2005-2020),共16 587 749例患者。
- 纳入78 852例房颤患者,年龄40-75岁,无既往卒中,未处方口服抗凝药。
- 女性28 590例(36.3%),男性50 262例(63.7%),中位年龄65.7岁(IQR 58.5-70.9)。
- 采用Cox风险比(HR),校正年龄、社会经济状态和合并症。
主要发现
- 缺血性卒中或动脉血栓栓塞无性别差异(校正HR 1.00,95%CI 0.94-1.07,P=0.87)。
临床怎么用
- 在房颤抗凝决策中,可考虑使用忽略性别的CHA2DS2-VA评分替代CHA2DS2-VASc以简化评估。
- 女性房颤患者主要复合终点风险较低,主要由死亡率较低驱动,卒中风险与男性相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The role of gender in decision-making for oral anticoagulation in patients with atrial fibrillation (AF) remains controversial. METHODS: The population cohort study used electronic healthcare records of 16 587 749 patients from UK primary care (2005-2020). Primary (composite of all-cause mortality, ischaemic stroke, or arterial thromboembolism) and secondary outcomes were analysed using Cox hazard ratios (HR), adjusted for age, socioeconomic status, and comorbidities. RESULTS: 78 852 patients were included with AF, aged 40-75 years, no prior stroke, and no prescription of oral anticoagulants. 28 590 (36.3%) were women, and 50 262 (63.7%) men. Median age was 65.7 years (interquartile range 58.5-70.9), with women being older and having other differences in comorbidities. During a total follow-up of 431 086 patient-years, women had a lower adjusted primary outcome rate with HR 0.89 vs. men (95% confidence interval [CI] 0.87-0.92; P < .001) and HR 0.87 after censoring for oral anticoagulation (95% CI 0.83-0.91; P < .001). This was driven by lower mortality in women (HR 0.86, 95% CI 0.83-0.89; P < .001). No difference was identified between women and men for the secondary outcomes of ischaemic stroke or arterial thromboembolism (adjusted HR 1.00, 95% CI 0.94-1.07; P = .87), any stroke or any thromboembolism (adjusted HR 1.02, 95% CI 0.96-1.07; P = .58), and incident vascular dementia (adjusted HR 1.13, 95% CI 0.97-1.32; P = .11). Clinical risk scores were only modest predictors of outcomes, with CHA2DS2-VA (ignoring gender) superior to CHA2DS2-VASc for primary outcomes in this population (receiver operating characteristic curve area 0.651 vs. 0.639; P < .001) and no interaction with gender (P = .45). CONCLUSIONS: Removal of gender from clinical risk scoring could simplify the approach to which patients with AF should be offered oral anticoagulation.
引用
- Champsi, Mobley, Subramanian, et al. Gender and contemporary risk of adverse events in atrial fibrillation. Eur Heart J. 2024. PMID: 39217497. doi:10.1093/eurheartj/ehae539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。